Clinical trials: Endometrial Carcinoma
Recurrent and Metastatic Endometrial Cancer
A Study of Letrozole in the Treatment of Endometrial Cancer
Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.
- Trial name
- NCT00333086
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Ovarian Cancer
A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT06738966
- Testing
- BL0175
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Endometrial Cancer, Sentinel Lymph Node
Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer
The standard of care for women with high risk endometrial cancer is the removal of all visible lymph nodes in the pelvis and lower abdomen to identify if disease has spread to these areas.
- Conditions
- Endometrial Cancer, Sentinel Lymph Node, Indocyanine Green
- Trial name
- EndoSLN (NCT01886066)
- Testing
- Indocyanine Green (ICG)
- Where
- 2 sites in Canada
- Volunteers
- 156 people
- Sponsor
- University Health Network, Toronto
Early Stage Endometrial Cancer, Sentinel Lymph Nodes
Sentinel Lymph Node Biopsy Versus Lymphadenectomy in Endometrial Cancer
To compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage endometrial cancer.
- Conditions
- Early Stage Endometrial Cancer, Sentinel Lymph Nodes, Lymphadenectomy
- Trial name
- NCT05048173
- Testing
- Sentinel lymph node mapping and biopsy, Lymphadenectomy
- Where
- Taiwan
- Volunteers
- 334 people
- Sponsor
- Far Eastern Memorial Hospital
Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
A Study to Assess the Efficacy and Safety of ABTL0812
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
- Trial name
- Endolung (NCT03366480)
- Testing
- ABTL0812 in combination with paclitaxel and carboplatin
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Ability Pharmaceuticals SL
Ovarian Cancer, Malignant Neoplasm of Uterus
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
This is an open-label, Phase 1 study with a dose expansion cohort of Sacituzumab Govitecan in Combination with Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer.
- Trial name
- NCT06040970
- Testing
- Sacituzumab, Cisplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Obese, Endometrial Cancer
Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer
80% of endometrial cancer patients are overweight or obese. Preclinical and clinical data have shown that caloric restriction (CR) protects against organ injury and decreases perioperative morbidity.
- Trial name
- NCT02665962
- Testing
- Perioperative Caloric Restriction Program
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Oophorectomy for Benign Reasons, Hysterectomy
Benign Reproductive Tissue Analysis for Endometrial Cancer Markers
Background: Endometrial cancer (cancer of the lining of the uterus) is the most common gynecologic cancer in the United States. Currently, there are no markers (components of blood and tissue that determine who might be at risk…
- Trial name
- NCT00481754
- Where
- United States
- Volunteers
- 359 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Carcinoma, Metastatic Carcinoma
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
The investigators hypothesize that the dual inhibition of mTORC1/mTORC2 by AZD2014 combined with inhibition of aromatase enzyme by anastrozole will act synergistically and may be an interesting therapeutic option for endometrial…
- Conditions
- Endometrial Carcinoma, Metastatic Carcinoma, Hormone Receptor Positive Tumor
- Trial name
- VICTORIA (NCT02730923)
- Testing
- AZD2014, Anastrozole
- Where
- 12 sites in France
- Volunteers
- 72 people
- Sponsor
- Centre Leon Berard
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Purpose of this study is to determine the effectiveness of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma.
- Trial name
- NCT00513786
- Testing
- Carboplatin, Paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- David O'Malley
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma.
- Trial name
- NCT02052128
- Testing
- onapristone
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Arno Therapeutics
Ovarian Cancer (OvCa), Fallopian Tube Cancers
Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy
This observational study aims to evaluate chemotherapy-induced taste alterations, sarcopenia, and malnutrition in patients with gynecologic malignancies (ovarian, fallopian tube, and endometrial cancer) treated with standard…
- Conditions
- Ovarian Cancer (OvCa), Fallopian Tube Cancers, Endometrial Cancer, Chemotherapy-Induced Taste Alteration
- Trial name
- GYM-TASTE (NCT07154966)
- Testing
- Standard Chemotherapy (Carboplatin-Paclitaxel)
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Ankara Etlik City Hospital
Oncology, Endometrial Cancer
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
This is a national observational retrospective multi-site chart review study of patients with advanced, recurrent or metastatic endometrial carcinoma.
- Conditions
- Oncology, Endometrial Cancer, Advanced Cancer, Recurrent Cancer
- Trial name
- ENDOVIE (NCT05364905)
- Testing
- Chemotherapy
- Where
- 30 sites in France
- Volunteers
- 200 people
- Sponsor
- ARCAGY/ GINECO GROUP
Advanced Solid Tumors
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04293094
- Testing
- AMG 650
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Volastra Therapeutics, Inc.
Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not…
- Conditions
- Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT03924245
- Testing
- Entinostat, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02059265
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 227 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or…
- Trial name
- NCT05277051
- Testing
- Remzistotug, Dostarlimab, Belrestotug
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 152 people
- Sponsor
- GlaxoSmithKline
Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Prognostic Biomarkers in Patients With Endometrial Cancer
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that…
- Conditions
- Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT01208467
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,824 people
- Sponsor
- Gynecologic Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.